Impact of Using Antiviral Therapy on COVID-19 Progression in ICU Patients: A Saudi Arabian Retrospective Analysis
- PMID: 38344559
- PMCID: PMC10858707
- DOI: 10.7759/cureus.52096
Impact of Using Antiviral Therapy on COVID-19 Progression in ICU Patients: A Saudi Arabian Retrospective Analysis
Abstract
Background The COVID-19 pandemic has posed an unprecedented challenge to the global healthcare system, necessitating effective therapeutic strategies to mitigate its impact. This study investigates the significance of early antiviral therapy in the context of intensive care units (ICUs) and its potential to influence the progression and outcomes of severe COVID-19 cases. Methodology This retrospective cohort study leveraged a diverse patient population with confirmed severe COVID-19 admitted to ICUs. A total of 1,250 patients were included in the analysis, and their medical records were comprehensively reviewed. The study aimed to assess the impact of early antiviral therapy on patient outcomes, focusing on the administration of remdesivir within the first 48 hours of ICU admission. Results In a study of 1,250 COVID-19 patients, early antiviral therapy with remdesivir significantly reduced ICU admissions by 30% (N = 225) compared to standard care (N = 525). The early therapy group also exhibited a 20% lower mortality rate (N = 120) than the control group (N = 150). Demographic associations with antiviral usage were observed. Kaletra was favored by females, non-Saudi individuals, and healthcare workers, while favipiravir was associated with gender. Remdesivir and ribavirin use were linked to gender and Saudi nationality, while oseltamivir was related to gender, Saudi nationality, and body mass index. Microbiological cure rates were 15.4%, with 84.6% not achieving it. ICU outcomes included 37.7% deaths, 55.7% home discharges, and 6.6% transfers, while hospital outcomes featured 38.5% deaths, 54.4% home discharges, and 7.1% transfers. Conclusions This study presents a comprehensive analysis of COVID-19 patient demographics, antiviral medication associations, and clinical outcomes. The findings highlight the significance of tailoring treatment strategies based on patient characteristics and viral history. These insights contribute to a deeper understanding of COVID-19 management and can inform clinical decision-making and further research in this field.
Keywords: antiviral interventions; covid-19 progression; early antiviral therapy; healthcare impact study; hospitalized covid-19 management; icu patient outcomes; patient recovery rates; retrospective analysis; saudi arabian study; treatment effectiveness.
Copyright © 2024, Alkhunaizi et al.
Conflict of interest statement
The authors have declared that no competing interests exist.
Similar articles
-
Impact of Corticosteroid Therapy on ICU Patient Outcomes in Severe COVID-19 Cases: A Retrospective Cohort Study in Saudi Arabia.Cureus. 2024 Feb 1;16(2):e53412. doi: 10.7759/cureus.53412. eCollection 2024 Feb. Cureus. 2024. PMID: 38435152 Free PMC article.
-
Impact of Tracheostomy on COVID-19 ICU Patients in Saudi Arabia: A Retrospective Analysis.Cureus. 2024 Jan 22;16(1):e52766. doi: 10.7759/cureus.52766. eCollection 2024 Jan. Cureus. 2024. PMID: 38389619 Free PMC article.
-
Overview of clinical outcome and therapeutic effectiveness of Favipiravir in patients with COVID-19 admitted to intensive care unit, Riyadh, Saudi Arabia.J Infect Public Health. 2022 Apr;15(4):389-394. doi: 10.1016/j.jiph.2022.01.013. Epub 2022 Feb 15. J Infect Public Health. 2022. PMID: 35299062 Free PMC article.
-
Body Mass Index as a Predictor of COVID-19 Severity in ICU Patients in Saudi Arabia: A Retrospective Analysis.Cureus. 2024 Jan 17;16(1):e52470. doi: 10.7759/cureus.52470. eCollection 2024 Jan. Cureus. 2024. PMID: 38371162 Free PMC article.
-
Global Impact of Coronavirus Disease 2019 Infection Requiring Admission to the ICU: A Systematic Review and Meta-analysis.Chest. 2021 Feb;159(2):524-536. doi: 10.1016/j.chest.2020.10.014. Epub 2020 Oct 15. Chest. 2021. PMID: 33069725 Free PMC article.
References
-
- Early administration of remdesivir to COVID-19 patients associates with higher recovery rate and lower need for ICU admission: a retrospective cohort study. Hussain Alsayed HA, Saheb Sharif-Askari F, Saheb Sharif-Askari N, Hussain AA, Hamid Q, Halwani R. http://10.1371 PLoS One. 2021;16:0. - PMC - PubMed
-
- The COVID-19 pandemic: a comprehensive review of taxonomy, genetics, epidemiology, diagnosis, treatment, and control. Helmy YA, Fawzy M, Elaswad A, Sobieh A, Kenney SP, Shehata AA. https://doi.org/10.3390/jcm9041225. J Clin Med. 2020;9:1225. - PMC - PubMed
-
- Impact of early SARS-CoV-2 antiviral therapy on disease progression. De Vito A, Colpani A, Saderi L, et al. https://doi.org/10.3390/v15010071. Viruses. 2022;15:71. - PMC - PubMed
-
- Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study. Wong CK, Au IC, Lau KT, Lau EH, Cowling BJ, Leung GM. http://10.1016. Lancet Infect Dis. 2022;22:1681–1693. - PMC - PubMed
-
- Effect of early oxygen therapy and antiviral treatment on disease progression in patients with COVID-19: a retrospective study of medical charts in China. Long L, Wu L, Chen L, et al. http://10.1371 PLoS Negl Trop Dis. 2021;15:0. - PMC - PubMed
LinkOut - more resources
Full Text Sources